{"entity":{"id":"sanofi","kind":"company","name":"Sanofi","aka":["Genzyme","Genzyme, a Sanofi Company","Kiadis Pharma","Aventis Pharmaceuticals","Aventis","ILEX Oncology Services, Incorporated","ILEX Oncology","Shantha Biotechnics Limited","Shantha Biotechnics"],"tldr":"Sanofi makes Sarclisa (isatuximab), now in a subcutaneous form approved in July 2026.","summary":"Sanofi, based in Paris and listed as SAN.PA, makes Sarclisa, or isatuximab, for multiple myeloma, now available in a subcutaneous form approved in July 2026 as Escena. Its oncology portfolio also includes cemiplimab with Regeneron, cabazitaxel, alemtuzumab, belumosudil, and avapritinib from its 2025 acquisition of Blueprint Medicines, while tusamitamab ravtansine was discontinued and a lead-212 DOTAMTATE radiopharmaceutical comes through RadioMedix. OnCo links it to myeloma, GIST, neuroendocrine tumours and skin cancers, to the EMPOWER-Cervical 1 trial, to CD52 as a target and to Sanofi Ventures. Whether the Blueprint purchase marks a durable commitment to oncology is the open question. Isatuximab and avapritinib have their own pages.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.sanofi.com"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":["immunotherapy","targeted-therapy"],"technologies":[],"targets":[],"drugs":["elenestinib","adg126","buserelin","fludarabine"],"companies":["amunix-pharmaceuticals","blueprint-medicines"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05704049","nct03731260","nct07692204","nct04270409","nct07629960","nct05584670"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Paris","country":"FR","companyType":"pharma","website":"https://www.sanofi.com","ticker":"SAN.PA","investors":[],"funding":[]},"route":"/companies/sanofi/","neighbours":{"cancer":[{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/"},{"id":"gist","kind":"cancer","name":"Gastrointestinal stromal tumour (GIST)","route":"/cancers/gist/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"alphamedix","kind":"drug","name":"212Pb-DOTAMTATE","route":"/drugs/alphamedix/"},{"id":"adg126","kind":"drug","name":"ADG126","route":"/drugs/adg126/"},{"id":"alemtuzumab","kind":"drug","name":"Alemtuzumab","route":"/drugs/alemtuzumab/"},{"id":"avapritinib","kind":"drug","name":"Avapritinib","route":"/drugs/avapritinib/"},{"id":"belumosudil","kind":"drug","name":"Belumosudil","route":"/drugs/belumosudil/"},{"id":"buserelin","kind":"drug","name":"Buserelin","route":"/drugs/buserelin/"},{"id":"cabazitaxel","kind":"drug","name":"Cabazitaxel","route":"/drugs/cabazitaxel/"},{"id":"clofarabine","kind":"drug","name":"Clofarabine","route":"/drugs/clofarabine/"},{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"elenestinib","kind":"drug","name":"Elenestinib","route":"/drugs/elenestinib/"},{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/"},{"id":"iniparib","kind":"drug","name":"Iniparib","route":"/drugs/iniparib/"},{"id":"isatuximab","kind":"drug","name":"Isatuximab","route":"/drugs/isatuximab/"},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/"},{"id":"plerixafor","kind":"drug","name":"Plerixafor","route":"/drugs/plerixafor/"},{"id":"rasburicase","kind":"drug","name":"Rasburicase","route":"/drugs/rasburicase/"},{"id":"thyrotropin-alfa","kind":"drug","name":"Thyrotropin alfa","route":"/drugs/thyrotropin-alfa/"},{"id":"tusamitamab-ravtansine","kind":"drug","name":"Tusamitamab ravtansine","route":"/drugs/tusamitamab-ravtansine/"},{"id":"vandetanib","kind":"drug","name":"Vandetanib","route":"/drugs/vandetanib/"},{"id":"ziv-aflibercept","kind":"drug","name":"Ziv-aflibercept","route":"/drugs/ziv-aflibercept/"}],"company":[{"id":"amunix-pharmaceuticals","kind":"company","name":"Amunix Pharmaceuticals","route":"/companies/amunix-pharmaceuticals/"},{"id":"blueprint-medicines","kind":"company","name":"Blueprint Medicines","route":"/companies/blueprint-medicines/"},{"id":"radiomedix","kind":"company","name":"RadioMedix","route":"/companies/radiomedix/"},{"id":"sanofi-ventures","kind":"company","name":"Sanofi Ventures","route":"/companies/sanofi-ventures/"}],"trial":[{"id":"nct04910685","kind":"trial","name":"(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis","route":"/trials/nct04910685/"},{"id":"nct03731260","kind":"trial","name":"(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo ","route":"/trials/nct03731260/"},{"id":"nct07692204","kind":"trial","name":"A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer","route":"/trials/nct07692204/"},{"id":"nct07629960","kind":"trial","name":"A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations","route":"/trials/nct07629960/"},{"id":"nct05584670","kind":"trial","name":"A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors","route":"/trials/nct05584670/"},{"id":"nct00295763","kind":"trial","name":"A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen","route":"/trials/nct00295763/"},{"id":"nct07133425","kind":"trial","name":"A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer","route":"/trials/nct07133425/"},{"id":"nct00938652","kind":"trial","name":"A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer","route":"/trials/nct00938652/"},{"id":"nct01882868","kind":"trial","name":"A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan","route":"/trials/nct01882868/"},{"id":"nct05704049","kind":"trial","name":"A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory","route":"/trials/nct05704049/"},{"id":"alphamedix-02","kind":"trial","name":"ALPHAMEDIX-02","route":"/trials/alphamedix-02/"},{"id":"c-post","kind":"trial","name":"C-POST (cemiplimab after surgery and radiotherapy for high-risk skin squamous cell carcinoma)","route":"/trials/c-post/"},{"id":"card","kind":"trial","name":"CARD","route":"/trials/card/"},{"id":"cemiplimab-advanced-bcc","kind":"trial","name":"Cemiplimab in basal cell carcinoma after a hedgehog inhibitor","route":"/trials/cemiplimab-advanced-bcc/"},{"id":"classic","kind":"trial","name":"CLASSIC","route":"/trials/classic/"},{"id":"empower-cervical-1","kind":"trial","name":"EMPOWER-Cervical 1 / GOG-3016 / ENGOT-cx9","route":"/trials/empower-cervical-1/"},{"id":"empower-cscc-1","kind":"trial","name":"EMPOWER-CSCC-1","route":"/trials/empower-cscc-1/"},{"id":"empower-lung-1","kind":"trial","name":"EMPOWER-Lung 1","route":"/trials/empower-lung-1/"},{"id":"nct01767714","kind":"trial","name":"Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation","route":"/trials/nct01767714/"},{"id":"firstana","kind":"trial","name":"FIRSTANA","route":"/trials/firstana/"},{"id":"getug-afu-15","kind":"trial","name":"GETUG-AFU 15","route":"/trials/getug-afu-15/"},{"id":"imroz","kind":"trial","name":"IMROZ","route":"/trials/imroz/"},{"id":"nct04270409","kind":"trial","name":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","route":"/trials/nct04270409/"},{"id":"nct00103662","kind":"trial","name":"Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients","route":"/trials/nct00103662/"},{"id":"mosaic","kind":"trial","name":"MOSAIC","route":"/trials/mosaic/"},{"id":"neoadjuvant-cemiplimab-cscc","kind":"trial","name":"Neoadjuvant cemiplimab for resectable stage II to IV skin squamous cell carcinoma","route":"/trials/neoadjuvant-cemiplimab-cscc/"},{"id":"proselica","kind":"trial","name":"PROSELICA","route":"/trials/proselica/"},{"id":"rockstar","kind":"trial","name":"ROCKstar","route":"/trials/rockstar/"},{"id":"nct04154956","kind":"trial","name":"SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients","route":"/trials/nct04154956/"},{"id":"nct01045304","kind":"trial","name":"Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct01045304/"},{"id":"tax-327","kind":"trial","name":"TAX 327","route":"/trials/tax-327/"},{"id":"tropic","kind":"trial","name":"TROPIC","route":"/trials/tropic/"},{"id":"nct04524689","kind":"trial","name":"Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC","route":"/trials/nct04524689/"},{"id":"nct04659603","kind":"trial","name":"Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors","route":"/trials/nct04659603/"},{"id":"nct01204125","kind":"trial","name":"Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients","route":"/trials/nct01204125/"},{"id":"velour","kind":"trial","name":"VELOUR","route":"/trials/velour/"},{"id":"zeta","kind":"trial","name":"ZETA","route":"/trials/zeta/"}],"paper":[{"id":"paper-rockstar-blood-2021","kind":"paper","name":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study","route":"/key-papers/paper-rockstar-blood-2021/"},{"id":"paper-de-bono-tropic-cabazitaxel-lancet-2010","kind":"paper","name":"TROPIC: prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel","route":"/key-papers/paper-de-bono-tropic-cabazitaxel-lancet-2010/"}],"target":[{"id":"cd52","kind":"target","name":"CD52","route":"/targets/cd52/"}],"technology":[{"id":"bcg-vaccine-manufacturing","kind":"technology","name":"BCG manufacturing and the bladder cancer BCG shortage","route":"/technologies/bcg-vaccine-manufacturing/"}]}}